Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review - Scorecard - MDSpire

Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review

  • By

  • Dario S. Lopez Delgado

  • Miriam Gabriela Reyes-Zermeño

  • Elian David Sanjuanelo Lemus

  • Catherine G. Acosta-Celis

  • María Amparo Kantún-Marín

  • Martín Gomez-Lujan

  • Kevin Gabriel Fallaza-Moya

  • Oscar Muñoz-Chuquilín

  • Sandra Trujillo-Levano

  • Giancarlo Gutierrez-Chavez

  • Cesar Bonilla-Asalde

  • Oriana Rivera-Lozada

  • Joshuan J. Barboza

  • July 6, 2026

  • 0 min

Share

Clinical Scorecard: Genomic and Phenotypic Approaches to Tailored Pharmacotherapy for Obesity: A Comprehensive Review

At a Glance

CategoryDetail
ConditionObesity
Key MechanismsInterindividual variability in response to anti-obesity medications influenced by genetic and phenotypic factors.
Target PopulationIndividuals with obesity who are candidates for pharmacotherapy.
Care SettingClinical and experimental research environments.

Key Highlights

  • Obesity is a chronic, heterogeneous disease with significant variability in treatment response.
  • Early on-treatment weight change is a key predictor of long-term outcomes.
  • Phenotype-guided approaches can enhance medication selection for obesity treatment.
  • Genomic tools are promising but not yet ready for routine clinical use.
  • Weight regain is common after treatment discontinuation, emphasizing the need for chronic care.

Guideline-Based Recommendations

Diagnosis

  • Utilize clinical, metabolic, and behavioral phenotypes for obesity diagnosis.

Management

  • Implement phenotype-guided treatment strategies for anti-obesity pharmacotherapy.

Monitoring & Follow-up

  • Assess early weight change within the first 12-16 weeks of treatment.

Risks

  • Consider interindividual variability in response and potential for weight regain.

Patient & Prescribing Data

Patients with obesity requiring pharmacotherapy.

Current pharmacotherapies show variability in efficacy and tolerability based on phenotypic and genomic factors.

Clinical Best Practices

  • Incorporate phenotypic classification into treatment decision-making.
  • Monitor adherence and tolerability proactively during treatment.
  • Utilize structured frameworks for early-response monitoring.

Related Resources & Content

Original Source(s)

Phenotypic and genomic frameworks for precision pharmacotherapy in obesity: a narrative review

  • by Dario S. Lopez Delgado, Miriam Gabriela Reyes-Zermeño, Elian David Sanjuanelo Lemus, Catherine G. Acosta-Celis, María Amparo Kantún-Marín, Martín Gomez-Lujan, Kevin Gabriel Fallaza-Moya, Oscar Muñoz-Chuquilín, Sandra Trujillo-Levano, Giancarlo Gutierrez-Chavez, Cesar Bonilla-Asalde, Oriana Rivera-Lozada, Joshuan J. Barboza

  • July 6, 2026

Related Content

Incretin-based cardiovascular protection beyond diabetes: evidence, mechanisms, and therapeutic frontiers from GLP-1 receptor agonists to multi-agonist therapy

Metabolic Health Tied to Dementia

In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.

Comparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis